|
1
|
Miller K, Wang M, Gralow J, et al:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miles DW, Chan A, Dirix LY, et al: Phase
III study of bevacizumab plus docetaxel compared with placebo plus
docetaxel for the first-line treatment of human epidermal growth
factor receptor 2-negative metastatic breast cancer. J Clin Oncol.
28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Robert NJ, Diéras V, Glaspy J, et al:
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III
trial of chemotherapy with or without bevacizumab for first-line
treatment of human epidermal growth factor receptor 2-negative,
locally recurrent or metastatic breast cancer. J Clin Oncol.
29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lang I, Brodowicz T, Ryvo L, et al:
Central European Cooperative Oncology Group: Bevacizumab plus
paclitaxel versus bevacizumab plus capecitabine as first-line
treatment for HER2-negative metastatic breast cancer: Interim
efficacy results of the randomised, open-label, non-inferiority,
phase 3 TURANDOT trial. Lancet Oncol. 14:125–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brufsky AM, Hurvitz S, Perez E, Swamy R,
Valero V, ONeill V and Rugo HS: RIBBON-2: A randomized,
double-blind, placebo-controlled, phase III trial evaluating the
efficacy and safety of bevacizumab in combination with chemotherapy
for second-line treatment of human epidermal growth factor receptor
2-negative metastatic breast cancer. J Clin Oncol. 29:4286–4293.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: Role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jain RK: Normalizing tumor vasculature
with anti-angiogenic therapy: A new paradigm for combination
therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Willett CG, Boucher Y, di Tomaso E, et al:
Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat Med. 10:145–147.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vakoc BJ, Lanning RM, Tyrrell JA, et al:
Three-dimensional microscopy of the tumor microenvironment in vivo
using optical frequency domain imaging. Nat Med. 15:1219–1223.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Winkler F, Kozin SV, Tong RT, et al:
Kinetics of vascular normalization by VEGFR2 blockade governs brain
tumor response to radiation: Role of oxygenation, angiopoietin-1
and matrix metalloproteinases. Cancer Cell. 6:553–563. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jain RK: Taming vessels to treat cancer.
Sci Am. 298:56–63. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gianni L, Romieu GH, Lichinitser M, et al:
AVEREL: A randomized phase III trial evaluating bevacizumab in
combination with docetaxel and trastuzumab as first-line therapy
for her2-positive locally recurrent/metastatic breast cancer. J
Clin Oncol. 31:1719–1725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miles DW, de Haas SL, Dirix LY, et al:
Biomarker results from the AVADO phase 3 trial of first-line
bevacizumab plus docetaxel for HER2-negative metastatic breast
cancer. Br J Cancer. 108:1052–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hegde PS, Jubb AM, Chen D, et al:
Predictive impact of circulating vascular endothelial growth factor
in four phase III trials evaluating bevacizumab. Clin Cancer Res.
19:929–937. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goel S, Duda DG, Xu L, et al:
Normalization of the vasculature for treatment of cancer and other
diseases. Physiol Rev. 91:1071–1121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goel S, Wong AH and Jain RK: Vascular
normalization as a therapeutic strategy for malignant and
nonmalignant disease. Cold Spring Harb Perspect Med. 2:a0064862012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giuliano S and Pagès G: Mechanisms of
resistance to anti-angiogenesis therapies. Biochimie. 95:1110–1119.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan F, Chen Y, Dellian M, Safabakhsh N,
Ferrara N and Jain RK: Time-dependent vascular regression and
permeability changes in established human tumor xenografts induced
by an anti-vascular endothelial growth factor/vascular permeability
factor antibody. Proc Natl Acad Sci USA. 93:14765–14770. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dickler MN, Barry WT, Cirrincione CT,
Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake D, Hahn
OM, et al: Phase III trial evaluating the addition of bevacizumab
to letrozole as first-line endocrine therapy for treatment of
hormone-receptor positive advanced breast cancer: CALGB 40503
(Alliance). J Clin Oncol. 33:(Suppl). 5012015.PubMed/NCBI
|
|
20
|
Bragalone DL: Drug Information Handbook
for Oncology. 10th. Lexicomp; Hudson, OH: pp. 501–514. 2012
|
